TTR rs121918504: What Your Genotype Means

What each genotype means

Genomic Location and the Nature of the Variant

The rs121918504 single nucleotide polymorphism is located on chromosome 18 within the coding region of the transthyretin (TTR) gene. At the nucleotide level on the forward genomic strand, the reference allele is guanine (G) and the alternative allele is adenine (A). This substitution alters a single codon, substituting the amino acid methionine for valine. In legacy medical literature, this change is famously referred to as Val30Met (or V30M), referencing the mature cleaved protein sequence. In modern HGVS nomenclature, which includes the 20-amino-acid signal peptide sequence, it is formally designated as p.Val50Met. This point mutation does not ablate protein synthesis entirely; instead, it subtly alters the biophysical properties of the resulting polypeptide chain. Because the variant changes an essential amino acid within the core structure of the protein, it directly affects how individual subunits assemble and maintain their stable quaternary arrangement.

Biological Role of the Transthyretin (TTR) Gene

The TTR gene provides the biological blueprint for transthyretin, a transport protein synthesized primarily by hepatocytes in the liver, with secondary production in the retinal pigment epithelium and the brain choroid plexus. In normal human physiology, four identical transthyretin monomers assemble into a stable four-part complex known as a homotetramer. This tetramer circulates in the bloodstream and cerebrospinal fluid, serving two critical physiological roles: carrying the thyroid hormone thyroxine (T4) and transporting retinol (vitamin A) via binding to retinol-binding protein. Under typical circumstances, the tetrameric configuration is energetically stable and shields hydrophobic regions from the aqueous environment. However, when the Val30Met alteration is present, the tetramer becomes structurally destabilized. It dissociates more readily into constituent monomers, which can misfold, aggregate into oligomers, and ultimately polymerize into insoluble cross-beta amyloid fibrils that deposit throughout peripheral tissues.

Clinical Evidence and Phenotypic Patterns

Extensive clinical literature identifies rs121918504 as a pathogenic variant associated with hereditary transthyretin-mediated amyloidosis (ATTRv), historically termed familial amyloid polyneuropathy (FAP). While evidence robustly demonstrates its causal role in familial aggregation of the disease, clinical penetrance is incomplete and heavily influenced by age, sex, and geographic background. Carriers often present in one of two major phenotypic patterns: early-onset disease, which frequently emerges in the third or fourth decade of life and is dominated by sensory-motor and autonomic neuropathy, or late-onset disease, which typically presents after age 50 or 60 and often involves cardiac tissue alongside progressive neuropathy. Although ClinVar and medical genetic databases categorize the variant as pathogenic, penetrance varies widely; a carrier may remain entirely asymptomatic throughout life, indicating that possession of the allele represents heightened lifetime susceptibility rather than an absolute medical destiny.

Global Frequencies and Founder Populations

On a global scale, the rs121918504 alternative allele is exceptionally rare, appearing in standard multi-ancestry population databases like gnomAD at frequencies well below 0.1 percent. Despite this widespread global rarity, the variant is markedly enriched in specific geographic founder populations due to historical bottlenecks. The highest concentrations of carriers have been documented in northern Portugal (particularly the Póvoa de Varzim and Vila do Conde regions), northern Sweden (notably Skellefteå and Piteå), and localized pockets in Japan (such as Nagano and Kumamoto). In certain northern Swedish communities, carrier frequencies can exceed 1 percent, although penetrance there is lower, often presenting as late-onset disease. In contrast, Portuguese carriers exhibit much higher penetrance and earlier symptom onset, underscoring how genetic background and non-coding modifier loci shape disease presentation across different ancestral groups.

Navigating Results: Scope and Limitations

Genetic data regarding rs121918504 carries important personal context, but raw data cannot provide a clinical diagnosis or predict if and when symptoms might emerge. Identifying an alternative allele on a consumer genotyping platform does not indicate active disease, nor does a reference genotype completely eliminate the possibility of amyloidosis, which can occasionally occur from other rare TTR variants or through wild-type protein aggregation with age. Because direct-to-consumer arrays can yield false-positive results on rare variants, any unexpected finding requires confirmation via clinical-grade Sanger sequencing or targeted gene panels ordered by a physician. Individuals with questions about a personal or family history of neuropathy or cardiomyopathy should consult a medical geneticist or certified genetic counselor to evaluate validated testing pathways and family health context safely.

Frequently asked questions

Sources & further reading

Related variants in TTR